...
首页> 外文期刊>Journal of International Medical Research >Current management of refractory ascites in patients with cirrhosis
【24h】

Current management of refractory ascites in patients with cirrhosis

机译:肝硬化患者难治性腹水的当前管理

获取原文
           

摘要

Liver cirrhosis is a health problem worldwide, and ascites is its principal symptom. Refractory ascites is intractable and occurs in 5%–10% of all patients with ascites due to cirrhosis. Refractory ascites leads to a poor quality of life and high mortality rate. Ascites develops as a result of portal hypertension, which leads to water–sodium retention and renal failure. Various therapeutic measures can be used for refractory ascites, including large-volume paracentesis, transjugular intrahepatic portosystemic shunt, vasoconstrictive drugs, and an automated low-flow ascites pump system. However, ascites generally can be resolved only by liver transplantation. Because not all patients can undergo liver transplantation, traditional approaches are still used to treat refractory ascites. The choice of treatment modality for refractory ascites depends, among other factors, on the condition of the patient.
机译:肝硬化是全世界的健康问题,腹水是其主要症状。顽固性腹水是顽固性的,在肝硬化引起的所有腹水患者中占5%–10%。顽固性腹水导致生活质量差和高死亡率。腹水是门脉高压的结果,导致水钠retention留和肾功能衰竭。各种治疗措施可用于难治性腹水,包括大容量穿刺,经颈静脉肝内门体分流术,血管收缩药和自动低流量腹水泵系统。但是,腹水一般只能通过肝移植来解决。由于并非所有患者都可以进行肝移植,因此传统方法仍用于治疗难治性腹水。除其他因素外,难治性腹水的治疗方式选择取决于患者的状况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号